Escitalopram in obsessive-compulsive disorder: A randomized, placebo-controlled, paroxetine-referenced, fixed-dose, 24-week study

Current Medical Research and Opinion

Volumn 23, Issue 4, 2007, Pages 701-711

  Stein, Dan J ^a,b,e   Andersen, Elisabeth Wreford ^c   Tonnoir, Brigitte ^c   Fineberg, Naomi ^d  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c H LUNDBECK A S   (Denmark)

^d UNIVERSITY OF HERTFORDSHIRE   (United Kingdom)

^e UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

Brown obsessive compulsive scale; Escitalopram; Fixed dose; Obsessive compulsive disorder; OCD; Paroxetine; Y BOCS; Yale

Indexed keywords

ESCITALOPRAM; PAROXETINE; PLACEBO;

ADULT; ANOREXIA; ANXIETY; ARTICLE; BLOOD PRESSURE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DELAYED EJACULATION; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EJACULATION DISORDER; ERECTILE DYSFUNCTION; FATIGUE; FEMALE; HEADACHE; HUMAN; HYPERHIDROSIS; INFLUENZA; INSOMNIA; LIBIDO; MAJOR CLINICAL STUDY; MALE; NAUSEA; OBSESSIVE COMPULSIVE DISORDER; PULSE RATE; RANDOMIZED CONTROLLED TRIAL; REMISSION; RHINOPHARYNGITIS; SIDE EFFECT; SOMNOLENCE; TREATMENT OUTCOME; TREATMENT RESPONSE; TREMOR; UPPER ABDOMINAL PAIN; XEROSTOMIA;

ADULT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; CITALOPRAM; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; OBSESSIVE-COMPULSIVE DISORDER; PAROXETINE; PATIENT DROPOUTS; PLACEBOS; REFERENCE STANDARDS; REMISSION INDUCTION; TREATMENT OUTCOME;

EID: 34247364531     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079907X178838     Document Type: Article

References (35)

1. Karno M, Goldin JM, Sorenson S B, et al. The epidemiology of obsessive compulsive disorder in five US communities. Arch Gen Psychiatry 1988;45:1094-9
2. Horwath E, Weissman MM. The epidemiology and cross-national presentation of obsessive-compulsive disorder. Psychiatr Clin North Am 2000;23:493-507
3. Murray CJL, Lopez AD. Global Burden of Disease: a comprehensive assessment of mortality and morbidity from diseases, injuries and risk factors in 1990 and projected to 2020, Vol I. Harvard: World Health Organization, 1996
4. Stein DJ, Allen A, Bobes J, et al. Quality of life in obsessive-compulsive disorder. CNS Spectr 2000;5 (S4):37-9
5. Dupont RL, Rice DP, Shiraki S, et al. Economic costs of obsessive-compulsive disorder. Med Interface 1995;8:102-9
6. Hollander E, Stein, DJ, Broatch J, et al. A pharmacoeconomic and quality of life study of obsessive-compulsive disorder. CNS Spectr 1997;2:16-25
7. Whiteside SP, Port JD, Abramowitz JS. A meta-analysis of functional neuroimaging in obsessive-compulsive disorder. Psychiatry Res 2004;132:69-79
8. Mataix-Cols D, Rosario-Campos MC, Leckman JF. A multidimensional model of obsessive-compulsive disorder. Am J Psychiatry 2005;162:228-38
9. Stein DJ. Seminar on obsessive-compulsive disorder. Lancet 2002;360:397-405
10. Stein DJ, Fineberg N, Seedat S. An integrated approach to the treatment of OCD. In: Fineberg, N, Marazziti, D, Stein DJ, eds. Obsessive-Compulsive Disorder: A Practical Guide. London: Martin Dunitz, 2001
11. Ozaki N, Goldman D, Kaye WH, et al. Serotonin transporter missense mutation associated with a complex neuropsychiatric phenotype. Mol Psychiatry 2003;8:933-6
12. 2A receptor binding in the caudate nuclei. Int J Neuropsychopharmacol 2005;8:391-401
13. Thoren P, Åsberg M, Bertilsson L, et al. Clomipramine treatment of obsessive-compulsive disorder. II. Biochemical aspects. Arch Gen Psychiatry 1980;37:1289-94
14. Zohar J, Insel TR. Obsessive-compulsive disorder: psychobiological approaches to diagnosis, treatment, and pathophysiology. Biol Psychiatry 1987;22 667-87
15. Joel D, Doljansky J, Roz N, et al. Role of the orbital cortex and of the serotonergic system in a rat model of obsessive compulsive disorder. Neuroscience 2005;130:25-36
16. Eddy KT, Dutra L, Bradley R, et al. A multidimensional meta-analysis of psychotherapy and pharmacotherapy for obsessive-compulsive disorder. Clin Psychol Rev 2004;24:1011-30
17. Ackerman DL, Greenland S. Multivariate meta-analysis of controlled drug studies for obsessive-compulsive disorder. J Clin Psychopharmacol 2002;22:309-17
18. Bandelow B, Zohar J, Hollander E, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and posttraumatic stress disorders. World J Biol Psychiatry 2002;3:171-99
19. Baldwin DS, Anderson IM, Nutt DJ, et al. Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2005;19:567-96
20. Fineberg NA, Gale TM. Evidence-based pharmacotherapy of obsessive-compulsive disorder. Int J Neuropsychopharmacol 2005;8:107-29
21. Sánchez C, Bøgesø KP, Ebert B, et al. Escitalopram versus citalopram: the surprising role of the R-enantiomer. Psychopharmacology 2004;174:163-76
22. Bielski RJ, Bose A, Chang CC. A double-blind comparison of escitalopram and paroxetine in the long-term treatment of generalized anxiety disorder. Ann Clin Psychiatry 2005;17: 65-9
23. Lader M, Stender K, Burger V, et al. Efficacy and tolerability of escitalopram in 12- and 24-week treatment of social anxiety disorder: randomized, double-blind, placebo-controlled, fixed-dose study. Depress Anxiety 2004;19:241-8
24. Sheehan DV, Lecrubier Y, Sheehan KH, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 1998;59:22-33
25. Goodman WK, Price LH, Rasmussen SA, et al. The Yale-Brown Obsessive Compulsive Scale. I. Development, use, and reliability. Arch Gen Psychiatry 1989;46:1006-11
26. Montgomery SA, Åsberg, M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979;134:382-9
27. Insel TR, Murphy DL, Cohen R M, et al. National Institute of Mental Health Obsessive-Compulsive Scale (NIMH-OC). Arch Gen Psychiatry 1983;46:5-12
28. Guy W. ECDEU Assessment Manual for Psychopharmacology, revised. US Dept Health, Education, and Welfare publication (ADM) 76-338. 1976. Rockville, MD, National Institute of Mental Health
29. Stewart SE, Geller DA, Jenike M, et al. Long-term outcome of pediatric obsessive-compulsive disorder: a meta-analysis and qualitative review of the literature. Acta Psych Scand 2004;110:4-13
30. Montgomery SA, Kasper S, Stein DJ, et al. Citalopram 20 mg, 40 mg and 60 mg are all effective and well tolerated compared with placebo in obsessive compulsive disorder. Int Clin Psychopharmacol 2001;16:75-86
31. Pallanti S, Hollander E, Bienstock C, et al. Treatment non-response in OCD: methodological issues and operational definitions. Int Clin Psychopharmacol 2002;5:181-91
32. Ballenger JC. Treatment of anxiety disorders to remission. J Clin Psychiatry 2001;62 (S12):5-9
33. Koran LM. Quality of life in obsessive-compulsive disorder. Psychiatr Clin North Am 2000;23:509-17
34. Di Bella D, Erzegovesi S, Cavallini MC, et al. Obsessive-compulsive disorder, 5-HTTLPR polymorphism and treatment response. Pharmacogenomics J 2002;2:176-81
35. Mataix-Cols D, Rauch SL, Manzo PA, et al. Use of factor-analyzed symptom dimensions to predict outcome with serotonin reuptake inhibitors and placebo in the treatment of obsessive-compulsive disorder. Am J Psychiatry 1999;156:1409-16